news

Samsung Bioepis fully acquired by Samsung Biologics

0
SHARES

After first payment of $1bn to Biogen, Samsung Biologics has now fully acquired Samsung Bioepis.

Samsung Biologics logo on a phone screen [Credit: viewimage/Shutterstock.com].

[Credit: viewimage/Shutterstock.com].

Samsung Biologics has completed the $2.3 billion purchase of Biogen’s stake in the Samsung Bioepis joint venture. Samsung Bioepis is a biopharmaceutical company dedicated to developing and manufacturing biosimilar medicines

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

The first payment of $1.0 billion has been completed and thus, pursuant to the terms of the acquisition agreement, Samsung Biologics has now fully acquired Samsung Bioepis as a wholly owned subsidiary. The remaining $1.3 billion payments will be made in instalments over two years.

“Today’s announcement marks a significant milestone for Samsung Biologics in our continued venture into the biosimilar business and accelerating biosimilar growth,” stated John Rim, Shief Executive Officer and President of Samsung Biologics. “By leveraging our extensive experience as a leading CDMO [contract development and manufacturing organisation], we will further contribute to saving lives of the patients and address a wide array of diseases.”

The purchase was funded by a portion of paid-in capital increase of KRW 3 trillion (approximately $2.5 billion) raised by issuing new shares, the proceeds of which will be used to fund the company’s strategic growth plans.

According to Samsung Biologics, the acquisition gives Samsung Bioepis improved autonomy and agility in business operations, accelerating sales growth, operating margin improvements, as well as biosimilar development capabilities and future performance in novel drug development.

Biogen and Samsung Bioepis will continue with their exclusive agreements, including the commercialisation of their current biosimilars portfolio including Benepali™, Flixabi™, Imraldi™ in Europe and the potential upcoming launches of Byooviz™ and the potential filings for SB15 in major markets worldwide.

Samsung Biologics has other ongoing projects, including the ongoing build of Plant 4, expected to be partially operational in October 2022, and work to secure additional land of 350,000m2 for Bio Campus II, which will be 30 percent larger than the size of the current site for future growth.

Share via
Share via